MIRACLE trial costs — Higher research and development expenses were mainly due to increased spending on the MIRACLE clinical trial and additional nonclinical studies.
Interim efficacy data — Positive interim results from the MIRACLE trial showed Annamycin treatment arms had complete remission rates at least three times higher than control in relapsed/refractory AML.
Cardiac safety profile — The MIRACLE trial continued to show no evidence of cardiotoxicity with Annamycin, supporting its differentiated safety profile.
Key detail: Q2 loss per share was $1.40.
Cash runway extended into Q1 2027
Moleculin Biotech expects its cash position, including a recent $9.3 million raise, to fund operations into Q1 2027.
The US clinical-stage pharma firm reported no Q2 revenue.
MIRACLE trial interim data and outlook
The company said interim data from its MIRACLE trial showed remission rates three times higher than control.
Moleculin sees a MIRACLE trial enrollment milestone in September 2026, with an efficacy readout by February 2027. The company expects to initiate MIRACLE trial Part B in 1H 2027 after dose selection.
